Mary Caffrey

Allo-CAR-NK cell therapy shows promise in achieving long-term remission for patients with Waldenström lymphoma without chemotherapy.

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

ASH 2025 reveals groundbreaking trial data on fixed-duration therapies for chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma, enhancing patient outcomes and reducing costs.

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Leaders from the American Oncology Network discuss they help practices navigate the implementation of complex therapies, in ways that make sense for patients and work financially for practices.

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.

Leaders of OneOncology share how the managed services organization empowers independent oncology practices through advanced technology, clinical trials, and value-based care, enhancing patient-focused cancer treatment.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards.

A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.

PARADIGM showed azacitidine and venetoclax outperform induction chemotherapy in initial treatment of acute myeloid leukemia (AML).

Epcoritamab combined with rituximab and lenalidomide significantly improves outcomes for relapsed follicular lymphoma, setting a new treatment standard.

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

Families of children with acute lymphoblastic leukemia face significant financial toxicity, with many experiencing severe economic hardship during treatment.

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

Rusfertide shows promise in maintaining hematocrit control and improving quality of life for polycythemia vera patients, reducing phlebotomy needs significantly.

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

A white paper explores how biomarker testing enhances patient outcomes and what barriers prevent access in several common cancers.

Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.